LP-184 (Compound 6), referred to as an acylfulvene analog, demonstrates the ability to inhibit tumor growth with noteworthy anti-cancer efficacy observed across multiple cell lines, including ovarian, colon, prostate, and pancreatic.

HT29 cells:0.68 μM (IC50), OVCAR-3 cells:0.6 μM (IC50), AsPC1 cells:16 μM (IC50), PC3:0.14 μM (IC50)

LP-184 demonstrates inhibitory effects on the proliferation of HT29, OVCAR-3, AsPC-1, and PC-3 cancer cell lines, showcasing half-maximal growth inhibitory concentrations (GI50) of 0.68, 0.6, 16, and 0.14 μM, respectively[1]. Furthermore, it exhibits significant anticancer activity, with half-maximal inhibitory concentrations (IC50) measured at 800nM and 210nM during the thymidine incorporation into cellular DNA (2 hour) and Trypan blue (48 hour) assays, respectively[1].

LP-184 demonstrated significant anti-tumor efficacy in mice with MV522 tumors, achieving partial responses in 4 out of 6 cases at a dose of 7.5 mg/kg and in all cases at a 10 mg/kg dose when administered intraperitoneally over a 21-day period[1]. This highlights LP-184 as a potent agent for human anti-tumor therapy. Dosage administered: 7.5 and 10 mg/kg; method: intraperitoneal; duration: 21 days; outcome: considerable effectiveness in tumor reduction.